Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14626 - 14650 of 15153 in total
Diminazene, also known as Diminazine, 4,4'-(Diazoamino)benzamidine, 4,4'-(1-triazene-1,3-diyl)bis-benzenecarboximidamide, diminazine aceturate, or Diminazene aceturate, is a trypanocidal agent. Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. This compound belongs to the phenylhydrazines. These are compounds containing a phenylhydrazide moiety, which consists of a hydrazide substituent...
Experimental
Matched Description: … Major brands of Diminazene are Berenil, Pirocide, Ganasag, and Azidin. This substance is a solid. ... HTH-type transcriptional regulator QacR, trypsin-1, amiloride-sensitive amine oxidase [copper-containing], and
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Investigational
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Matched Description: … It was developed for the treatment and prevention of thromboembolic events. …
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Description: … 2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
Investigational
Matched Description: … antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and
PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms on Donepezil).
Investigational
Matched Description: … PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy …
Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing peptides. It is under investigation for the treatment of hyperphenylalaninemia.
Investigational
Matched Description: … Phelemin (PHE-MIP) is a methacrylic acid-based copolymer purified to bind to L-phenylalanine and L-phenylalanine-containing …
BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).
Investigational
Matched Description: … NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and
DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially...
Investigational
Matched Description: … suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and ... CD-10* or TOP** peptidases, such as prostate cancer, colorectal cancer, melanoma, pancreatic cancer and
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
Investigational
Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to citalopram.
Experimental
Matched Description: … It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. …
SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … It is being developed by Schering-Plough and Pharmacopeia. …
AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
Investigational
Matched Description: … immune response characteristics, that is designed to stimulate the patient's immune system to target and
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has R configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and
Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission).
Investigational
Matched Description: … trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and
Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction).
Investigational
Matched Description: … under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and
Displaying drugs 14626 - 14650 of 15153 in total